Neostigmine Methylsulfate Injection Recalled Due to Lack of Sterility Assurance
Nephron Sterile Compounding Center LLC is recalling Neostigmine Methylsulfate Injection due to lack of assurance of sterility. The recall affects 59,520 syringes distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Class II FDA recall for a sterile injectable medication where assurance of sterility cannot be provided. No illnesses or deaths have been reported, but the loss of sterility assurance in a critical-care injectable presents a risk of harm.
Plain-English summary
Nephron Sterile Compounding Center LLC is recalling Neostigmine Methylsulfate Injection, USP, 3 mg/3 mL (1 mg/mL) pre-filled syringes. This is a prescription-only medication. The recall was issued due to lack of assurance of sterility and affects 59,520 syringes distributed nationwide.
This is classified as an FDA Class II recall. The affected lot numbers are NE2002A (Exp. 7/14/2022), NE2003A (Exp. 7/24/2022), NE2006A (Exp. 8/1/2022), NE2007A (Exp. 8/9/2022), NE2008A (Exp. 8/18/2022), NE2009A (Exp. 8/27/2022), and NE2012D (Exp. 10/3/2022).
The recalled product
- Product
- Neostigmine Methylsulfate Injection, USP, 3 mg/3 mL (1 mg/mL) syringe, packaged in 5 x 3 mL Pre-Filled Syringes per carton, 6 x 5 Syringe Carton per case, Rx Only, Nephron 503B outsourcing facility, 4500 12th St. Extension, West Columbia, SC 29172, NDC: 69374-932-03
- Manufacturer
- Nephron Sterile Compounding Center LLC
- Category
- Drug — Injectable Compounded
- Hazard
- lack-of-sterility
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (14)
- Lots:NE2002A
- Exp. 7/14/2022
- NE2003A
- Exp. 7/24/2022
- NE2006A
- Exp. 8/1/2022
- NE2007A
- Exp. 8/9/2022
- NE2008A
- Exp. 8/18/2022
- NE2009A
- Exp. 8/27/2022
- NE2012D
- Exp. 10/3/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModeratePovi-One Povidone-Iodine 10% Topical Drug Recall for Sub Potency
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar Cinacalcet Tablets Recalled Due to CGMP Deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar (Cinacalcet Hydrochloride) Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-01